Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children
Whittle, H.; Jaffar, S.; Wansbrough, M.; Mendy, M.; Dumpis, U.; Collinson, A.; Hall, A.
BMJ 325(7364): 569
2002
ISSN/ISBN: 0959-8138 PMID: 12228132 DOI: 10.1136/bmj.325.7364.569Document Number: 243370
Objective To determine the duration of protection from hepatitis B vaccine given in infancy and early childhood. Design Cross sectional serological study of hepatitis B virus infection in children of various ages 14 years after the start of a trial of vaccination regimens. Setting Two villages in the Gambia. Participants Children and adolescents given hepatitis B vaccine in infancy or early childhood: 232 were aged 1-5 years, 225 aged 5-9 years, 220 aged 10-14 years, and 175 aged 15-19 years. Main outcome measures Vaccine efficacy against infection and against chronic infection in the different age groups. Results Vaccine efficacy against chronic hepatitis B virus carriage was 94% (95% confidence interval 89% to 97%), which did not vary significantly between the age groups. Efficacy against infection was 80% (76% to 84%). This was significantly lower in the oldest age group (65%, 56 to 73). Of the uninfected participants in this age group, 36% had no detectable hepatitis B virus surface antibody. Time since vaccination and a low peak antibody response were the most powerful risk factors for breakthrough infection (P < 0.001 in each case). Low peak antibody response was also a risk factor for chronic carriage (odds ratio 95, 19 to 466). Conclusions Children vaccinated in infancy are at increased risk of hepatitis B virus infection in the late teens. The risk of chronic carriage after sexual exposure needs further assessment to determine if booster vaccines are necessary.